Agnieszka Szypowska
Overview
Explore the profile of Agnieszka Szypowska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
643
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hummel S, Kassl A, Arnolds S, Achenbach P, Berner R, Casteels K, et al.
Contemp Clin Trials Commun
. 2025 Feb;
44:101434.
PMID: 39916680
Viral infections in the first year of life are associated with islet autoimmunity and type 1 diabetes risk. The Anti-Viral Action against Type 1 Diabetes Autoimmunity (AVAnT1A)- study is a...
2.
Hoffmann L, Kohls M, Arnolds S, Achenbach P, Bergholdt R, Bonifacio E, et al.
BMJ Open
. 2025 Jan;
15(1):e088522.
PMID: 39753267
Introduction: The identification of type 1 diabetes at an early presymptomatic stage has clinical benefits. These include a reduced risk of diabetic ketoacidosis (DKA) at the clinical manifestation of the...
3.
Szadkowska A, Chobot A, Glowinska-Olszewska B, Jarosz-Chobot P, Mianowska B, Mysliwiec M, et al.
Pediatr Endocrinol Diabetes Metab
. 2024 Oct;
30(3):132-147.
PMID: 39451186
Currently, hybrid closed loop (HCL) systems represent the most advantageous therapeutic option for people with diabetes requiring intensive insulin therapy. They make it possible to achieve optimal metabolic control of...
4.
Hendriks A, Marcovecchio M, Besser R, Bonifacio E, Casteels K, Elding Larsson H, et al.
Diabetes Metab Res Rev
. 2024 Feb;
40(2):e3777.
PMID: 38375753
Background/aim: Type 1 diabetes is an autoimmune disease that involves the development of autoantibodies against pancreatic islet beta-cell antigens, preceding clinical diagnosis by a period of preclinical disease activity. As...
5.
Groele L, Dzygalo K, Kowalska A, Szypowska A
BMJ Open
. 2024 Feb;
14(2):e076882.
PMID: 38341215
Introduction: Sphingolipids regulate proinsulin folding, insulin secretion and control beta cells apoptosis. Recent evidence has demonstrated that, among other factors, reduced amounts of sulfatide may be relevant in the development...
6.
Groele L, Szypowska A
Pediatr Endocrinol Diabetes Metab
. 2024 Jan;
29(4):209-213.
PMID: 38282489
No abstract available.
7.
Kowalczyk-Korcz E, Dyminska M, Szypowska A
Nutrients
. 2024 Jan;
16(2).
PMID: 38257156
Background: This study aimed to compare whether a super bolus (SB) is a more efficient strategy than a normal bolus (NB) for high glycemic index (h-GI) meals in children with...
8.
Jacobs A, Warnants M, Vollmuth V, Winkler C, Weiss A, Ziegler A, et al.
BMJ Paediatr Open
. 2024 Jan;
8(1).
PMID: 38216311
Background: Vitamin D insufficiency (VDI) may be a factor in the development of type 1 diabetes (T1D). The aim of this study is to investigate the presence and persistence of...
9.
Hummel S, Rosenberger S, von dem Berge T, Besser R, Casteels K, Hommel A, et al.
Diabetologia
. 2024 Jan;
67(4):670-678.
PMID: 38214711
Aims/hypothesis: The aim of this study was to determine whether BMI in early childhood was affected by the COVID-19 pandemic and containment measures, and whether it was associated with the...
10.
Ramos E, Dayan C, Chatenoud L, Sumnik Z, Simmons K, Szypowska A, et al.
N Engl J Med
. 2023 Oct;
389(23):2151-2161.
PMID: 37861217
Background: Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3)...